Clinical Research Directory
Browse clinical research sites, groups, and studies.
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Official title: Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-05-11
Completion Date
2027-12-31
Last Updated
2024-06-10
Healthy Volunteers
No
Conditions
Interventions
CAR-T cells
Infusion of multi-CAR-T cells
Locations (2)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health
Vladivostok, Russia